Abstract:Proc Amer Assoc Cancer Res, Volume 47, 2006 4662 Hepatocellular carcinoma (HCC) is one of the most common and lethal solid tumors in the world. HCC is typically refractory to almost all cytotoxic chemotherapeutic agents. OSU-03012 is a derivative of celecoxib, a cyclooxygenase (COX)-2 inhibitor. However, its primary mechanism of action is known as 3-phosphoinositide-dependent kinase-1 (PDK-1) inhibition and by which it induces apoptosis in certain cancer cells[Zhu J et al. , Cancer Res. 64:4309-18, 2004; Hsu AL et al. , J Biol. Chem . 275:11937-403. 2000]. This study sought to investigate if OSU-03012 may be effective in the treatment of HCC. OSU-03012 inhibited cell growth of Huh7, a human HCC cell line, in a dose-dependent manner, with IC50 at 1μM, which is well below the non-toxic serum concentration (5-20μM) in mice. Surprisingly, in this Huh7 cell model, western blotting analysis demonstrated that neither pPDK1 nor pAkt was suppressed by OSU-03012. Cell cycle analysis by flow cytometry indicated that OSU-03012 (5μM, 24h) significantly increased S-phase population, while did not alter sub-G1 population, suggesting that apoptosis is not a major mechanism of cell growth suppression. Western blotting analysis showed that OSU-03012 reduced protein level of cyclin D1. Furthermore, OSU-03012-treated cells exhibited cytoplasmic vacuoles which were positively stained by acridine orange and monodansylcadaverine, a phenomenon mimicking cell autophagy. The content in the OSU-03012-induced autophagosomes and its mechanistic linkage with the occurrence of autophagy-like cell death of Huh7 cells are under investigation. Together, our preliminary results indicate that OSU-03012 might be an effective therapeutic agent for HCC, but the mechanisms of action of this drug in HCC cells need to be further clarified. (This study was supported by grant DOH94-TD-B-111-001 from Department of Health, R.O.C. to National Clinical Research Center at National Taiwan University)

Novel Bioactive Hybrid Celecoxib-HDAC Inhibitor, Induces Apoptosis in Human Acute Lymphoblastic Leukemia Cells

A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells

Homoharringtonine is Synergistically Lethal with BCL-2 Inhibitor APG-2575 in Acute Myeloid Leukemia

A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells

Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells

Osu-03012, A Novel Celecoxib Derivative, Induces A Unique Autophagy-Like Cell Death In Human Hepatocellular Carcinoma Cells

Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax

Novel indole retinoid derivative induces apoptosis and cell cycle arrest and modulates AKT and ERK signaling in HL-60 cells

Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting LCK in acute lymphoblastic leukemia

[Synergistic Effect of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid with Imatinib on K562 Cells].

Simultaneous inhibition of FLT3 and HDAC by novel 6-ethylpyrazine-2-Carboxamide derivatives provides therapeutic advantages in acute myelocytic leukemia

A Novel SAHA-bendamustine Hybrid Induces Apoptosis of Leukemia Cells

Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine

Anti-leukemia effects of the novel synthetic 1-benzylindole derivative 21-900 in vitro and in vivo

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo

Novel Hybrid CHC from β-carboline and N-Hydroxyacrylamide Overcomes Drug-Resistant Hepatocellular Carcinoma by Promoting Apoptosis, DNA Damage, and Cell Cycle Arrest

Tetrahydro- β -carboline derivatives as potent histone deacetylase 6 inhibitors with broad-spectrum antiproliferative activity

Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2